Share
Save
A Practice Change for Patients With Severe Chronic, Clinically Unexplained Gastrointestinal Symptoms
This research project aims to test whether early interventions delivered remotely and prior to integrated care clinic appointments are effective. Patients with chronic unexplained gastrointestinal symptoms will initially undergo structured assessment of symptoms and wheat intolerance delivered remotely. Patients who continue to experience symptoms will then be randomised to a pre-consultation intervention ((a) standardised dietician supervised intervention, b) exercise intervention, c) internet delivered cognitive behavior therapy or d) nothing) followed by randomisation to the consultation intervention ((a) consultant-led outpatient clinic or b) a integrated care clinic depending on their response to the initial intervention.
Study details:
An Effectiveness-Implementation Hybrid Design with a two stage randomisation will be used to determine and compare efficacy and cost-effectiveness of different management approaches/interventions for patients with relevant, chronic, or relapsing gastrointestinal symptoms without concerning features and on the wait list for integrated care clinic at the Princess Alexandra Hospital. Approximately 200 patients will initially receive standardised assessment of symptoms and wheat intolerance. Those patients that continue to experience symptoms will then be randomised to a pre-consultation intervention (a) standardised dietician supervised intervention, b) exercise intervention, c) internet delivered cognitive behavior therapy or d) nothing) followed by randomisation to the consultation intervention (a) consultant-led outpatient clinic or b) an integrated care clinic conditional on their response to the initial intervention.
Specific aims of the study include Aim 1: Determine efficacy (symptom improvement) and cost-effectiveness (quality adjusted life years) of a structured, digital technology enabled approach for the management of patients with severe functional gastrointestinal disorders as compared to established service models; Aim 2: Identify response-predictors for the pre-clinical dietary intervention, internet delivered cognitive behavior therapy, exercise physiology and the various clinical interventions; Aim 3: Define acceptance of consumers and staff for the new service model relative to established models of care and Aim 4. To determine the dietary patterns of people with functional gastrointestinal disorders who are presenting with symptoms necessary to access tertiary care and to further examine changes in diet after a range of interventions delivered by telehealth.
Eligibility criteria
Researchers look for people who fit a certain description, called eligibility criteria. See if you qualify.
Inclusion criteria
Exclusion criteria
Eligibility
Age eligible for study : 18 and older
Healthy volunteers accepted : No
Gender eligible for study: All
Things to know
Study dates
Study start: 2023-05-01
Primary completion: 2025-10-30
Study completion finish: 2025-12-31
Study type
TREATMENT
Phase
NA
Trial ID
NCT05274854
Intervention or treatment
BEHAVIORAL: a)standardised dietician supervised intervention, b) exercise intervention, c) internet delivered cognitive behavior therapy or d) nothing
BEHAVIORAL: a) consultant-led outpatient clinic or b) a integrated care clinic
Conditions
- • Gastrointestinal Diseases
- • Irritable Bowel Syndrome
Condition: Gastrointestinal Diseases, Irritable Bowel Syndrome
BEHAVIORAL: a)standardised dietician supervised intervention, b) exercise intervention, c) internet delivered cognitive behavior therapy or d) nothing and other drugs
Woolloongabba, Queensland, Australia
Sponsor: The University of Queensland
Find a site
Closest Location:
Princess Alexandra Hospital
Research sites nearby
Select from list below to view details:
Princess Alexandra Hospital
Woolloongabba, Queensland, Australia
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
| Participant Group/Arm | Intervention/Treatment |
|---|---|
EXPERIMENTAL: Preconsultation Intervention
| BEHAVIORAL: a)standardised dietician supervised intervention, b) exercise intervention, c) internet delivered cognitive behavior therapy or d) nothing
|
EXPERIMENTAL: Consultation Intervention
| BEHAVIORAL: a) consultant-led outpatient clinic or b) a integrated care clinic
|
What is the study measuring?
Primary outcome
| Primary Outcome Measure | Primary Outcome Description | Primary Outcome Time Frame |
|---|---|---|
| Structured Assessment of Gastrointestinal Symptoms score | Structured Assessment of Gastrointestinal Symptoms score: Assesses impact of various GI symptoms. SAGIS scores will be used to measure symptom type and symptom severity. Scores can range from 0 to 88. Higher scores indicate greater severity of symptoms | Week 0 |
| Structured Assessment of Gastrointestinal Symptoms score | Structured Assessment of Gastrointestinal Symptoms score: Assesses impact of various GI symptoms. SAGIS scores will be used to measure symptom type and symptom severity. Scores can range from 0 to 88. Higher scores indicate greater severity of symptoms | Week 8 |
| Structured Assessment of Gastrointestinal Symptoms score | Structured Assessment of Gastrointestinal Symptoms score: Assesses impact of various GI symptoms. SAGIS scores will be used to measure symptom type and symptom severity. Scores can range from 0 to 88. Higher scores indicate greater severity of symptoms | Week 16 |
| Structured Assessment of Gastrointestinal Symptoms score | Structured Assessment of Gastrointestinal Symptoms score: Assesses impact of various GI symptoms. SAGIS scores will be used to measure symptom type and symptom severity. Scores can range from 0 to 88. Higher scores indicate greater severity of symptoms | Week 20 |
| Structured Assessment of Gastrointestinal Symptoms score | Structured Assessment of Gastrointestinal Symptoms score: Assesses impact of various GI symptoms. SAGIS scores will be used to measure symptom type and symptom severity. Scores can range from 0 to 88. Higher scores indicate greater severity of symptoms | Week 24 |
| Structured Assessment of Gastrointestinal Symptoms score | Structured Assessment of Gastrointestinal Symptoms score: Assesses impact of various GI symptoms. SAGIS scores will be used to measure symptom type and symptom severity. Scores can range from 0 to 88. Higher scores indicate greater severity of symptoms | Week 28 |
| Structured Assessment of Gastrointestinal Symptoms score | Structured Assessment of Gastrointestinal Symptoms score: Assesses impact of various GI symptoms. SAGIS scores will be used to measure symptom type and symptom severity. Scores can range from 0 to 88. Higher scores indicate greater severity of symptoms | Week 32 |
| Structured Assessment of Gastrointestinal Symptoms score | Structured Assessment of Gastrointestinal Symptoms score: Assesses impact of various GI symptoms. SAGIS scores will be used to measure symptom type and symptom severity. Scores can range from 0 to 88. Higher scores indicate greater severity of symptoms | Week 35 |
| Structured Assessment of Gastrointestinal Symptoms score | Structured Assessment of Gastrointestinal Symptoms score: Assesses impact of various GI symptoms. SAGIS scores will be used to measure symptom type and symptom severity. Scores can range from 0 to 88. Higher scores indicate greater severity of symptoms | Week 38 |
| Structured Assessment of Gastrointestinal Symptoms score | Structured Assessment of Gastrointestinal Symptoms score: Assesses impact of various GI symptoms. SAGIS scores will be used to measure symptom type and symptom severity. Scores can range from 0 to 88. Higher scores indicate greater severity of symptoms | Week 44 |
| European Quality of Life Five Dimension (EQ-5D) | The EQ-5D is a preference-based health related Quality of Life measure. The maximum score of 1 indicates the best health state | Week 0 |
| European Quality of Life Five Dimension (EQ-5D) | The EQ-5D is a preference-based health related Quality of Life measure. The maximum score of 1 indicates the best health state | Week 8 |
| European Quality of Life Five Dimension (EQ-5D) | The EQ-5D is a preference-based health related Quality of Life measure. The maximum score of 1 indicates the best health state | Week 16 |
| European Quality of Life Five Dimension (EQ-5D) | The EQ-5D is a preference-based health related Quality of Life measure. The maximum score of 1 indicates the best health state | Week 20 |
| European Quality of Life Five Dimension (EQ-5D) | The EQ-5D is a preference-based health related Quality of Life measure. The maximum score of 1 indicates the best health state | Week 24 |
| European Quality of Life Five Dimension (EQ-5D) | The EQ-5D is a preference-based health related Quality of Life measure. The maximum score of 1 indicates the best health state | Week 28 |
| European Quality of Life Five Dimension (EQ-5D) | The EQ-5D is a preference-based health related Quality of Life measure. The maximum score of 1 indicates the best health state | Week 32 |
| European Quality of Life Five Dimension (EQ-5D) | The EQ-5D is a preference-based health related Quality of Life measure. The maximum score of 1 indicates the best health state | Week 35 |
| European Quality of Life Five Dimension (EQ-5D) | The EQ-5D is a preference-based health related Quality of Life measure. The maximum score of 1 indicates the best health state | Week 38 |
| European Quality of Life Five Dimension (EQ-5D) | The EQ-5D is a preference-based health related Quality of Life measure. The maximum score of 1 indicates the best health state | Week 44 |
| Cost effectiveness | To assess the cost-effectiveness and given the expected impact of the intervention on patient quality of life, a cost-utility analysis (CUA) will be conducted. The analysis will capture direct medical and non- medical costs including out-of-pocket expenses and indirect costs (e.g., lost productivity) based upon resources consumed using unit prices from standard costing resources. Quality-adjusted life-year (QALYs) gained will be weighted by their utility score (using the EQ-5D) | Week 0 |
| Cost effectiveness | To assess the cost-effectiveness and given the expected impact of the intervention on patient quality of life, a cost-utility analysis (CUA) will be conducted. The analysis will capture direct medical and non- medical costs including out-of-pocket expenses and indirect costs (e.g., lost productivity) based upon resources consumed using unit prices from standard costing resources. Quality-adjusted life-year (QALYs) gained will be weighted by their utility score (using the EQ-5D) | Week 8 |
| Cost effectiveness | To assess the cost-effectiveness and given the expected impact of the intervention on patient quality of life, a cost-utility analysis (CUA) will be conducted. The analysis will capture direct medical and non- medical costs including out-of-pocket expenses and indirect costs (e.g., lost productivity) based upon resources consumed using unit prices from standard costing resources. Quality-adjusted life-year (QALYs) gained will be weighted by their utility score (using the EQ-5D) | Week 16 |
| Cost effectiveness | To assess the cost-effectiveness and given the expected impact of the intervention on patient quality of life, a cost-utility analysis (CUA) will be conducted. The analysis will capture direct medical and non- medical costs including out-of-pocket expenses and indirect costs (e.g., lost productivity) based upon resources consumed using unit prices from standard costing resources. Quality-adjusted life-year (QALYs) gained will be weighted by their utility score (using the EQ-5D) | Week 28 |
| Cost effectiveness | To assess the cost-effectiveness and given the expected impact of the intervention on patient quality of life, a cost-utility analysis (CUA) will be conducted. The analysis will capture direct medical and non- medical costs including out-of-pocket expenses and indirect costs (e.g., lost productivity) based upon resources consumed using unit prices from standard costing resources. Quality-adjusted life-year (QALYs) gained will be weighted by their utility score (using the EQ-5D) | Week 44 |
Secondary outcome
| Secondary Outcome Measure | Secondary Outcome Description | Secondary Outcome Time Frame |
|---|---|---|
| Hospital Anxiety and Depression Scale | Anxiety and Depression scores from the Hospital Anxiety and Depression Scale. Scores can range from 0 to 21 for each subscale of anxiety and depression, respectively. Higher scores indicate greater frequency of anxiety and depression. | Week 0 |
| Hospital Anxiety and Depression Scale | Anxiety and Depression scores from the Hospital Anxiety and Depression Scale. Scores can range from 0 to 21 for each subscale of anxiety and depression, respectively. Higher scores indicate greater frequency of anxiety and depression. | Week 16 |
| Hospital Anxiety and Depression Scale | Anxiety and Depression scores from the Hospital Anxiety and Depression Scale. Scores can range from 0 to 21 for each subscale of anxiety and depression, respectively. Higher scores indicate greater frequency of anxiety and depression. | Week 28 |
| Hospital Anxiety and Depression Scale | Anxiety and Depression scores from the Hospital Anxiety and Depression Scale. Scores can range from 0 to 21 for each subscale of anxiety and depression, respectively. Higher scores indicate greater frequency of anxiety and depression. | Week 44 |
| Microbiome | Total abundance and relative abundance of specific phyla of the microbiome | Week 0 |
| Microbiome | Total abundance and relative abundance of specific phyla of the microbiome | Week 16 |
| Microbiome | Total abundance and relative abundance of specific phyla of the microbiome | Week 28 |
| Microbiome | Total abundance and relative abundance of specific phyla of the microbiome | Week 44 |
| Acceptance of models of care by consumers and staff | For the pre-consultation and the 3- months intervention period, the consumer's net promotor score ('...I would recommend the service I received to a family member or friend yes/no..') will be determined and compared. With regard to the team providing services to the patients, all members providing care will respond to the following question in relation to specific treatment groups: '...I have been able to address the patient's problems yes/no..' | Week 16 |
| Acceptance of models of care by consumers and staff | For the pre-consultation and the 3- months intervention period, the consumer's net promotor score ('...I would recommend the service I received to a family member or friend yes/no..') will be determined and compared. With regard to the team providing services to the patients, all members providing care will respond to the following question in relation to specific treatment groups: '...I have been able to address the patient's problems yes/no..' | Week 28 |
Frequently Asked Questions
Please note: some questions and answers are submitted by anonymous patients or using AI, and have not been verified by Clinrol
No questions submitted. Be the first to ask a question!